ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

TEVA Teva Pharmaceutical Industries Ltd

14.08
0.00 (0.00%)
04 May 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Teva Pharmaceutical Industries Ltd NYSE:TEVA NYSE Depository Receipt
  Price Change % Change Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 14.08 14.16 13.96 14.15 7,051,252 01:00:00

Initial Statement of Beneficial Ownership (3)

04/10/2021 12:21pm

Edgar (US Regulatory)


FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Zaks Tal Zvi
2. Date of Event Requiring Statement (MM/DD/YYYY)
10/1/2021 

3. Issuer Name and Ticker or Trading Symbol

TEVA PHARMACEUTICAL INDUSTRIES LTD [TEVA]
(Last)        (First)        (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                          _____ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)

TEL AVIV, L3 6944020      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares

Explanation of Responses:

Remarks:
Exhibit List: Exhibit 24 - Power of Attorney
No securities are beneficially owned.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Zaks Tal Zvi
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.
124 DVORA HANEVI'A ST.,
TEL AVIV, L3 6944020
X



Signatures
/s/ Dov Bergwerk as attorney-in-fact for Tal Zvi Zaks10/4/2021
**Signature of Reporting PersonDate

1 Year Teva Pharmaceutical Indu... Chart

1 Year Teva Pharmaceutical Indu... Chart

1 Month Teva Pharmaceutical Indu... Chart

1 Month Teva Pharmaceutical Indu... Chart

Your Recent History

Delayed Upgrade Clock